HIFEM for Incontinence After Menopause High-Intensity Focused Electromagnetic (HIFEM)
NCT ID: NCT07260604
Last Updated: 2025-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
100 participants
INTERVENTIONAL
2026-10-15
2028-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A new type of treatment for stress, urge and mixed incontinence is now on the market, High-Intensity Focused Electromagnetic (HIFEM®) treatment. This involves electromagnetic stimulation that causes contractions in the pelvic floor muscles. The treatment is not painful or invasive and the patient sits clothed in the treatment chair. In Sweden, HIFEM® is mainly available outside of traditional healthcare and is very expensive. It is also often given by unauthorized actors.
We are now planning a study whose purpose is to evaluate the effect of HIFEM® on women over 65 years of age with stress incontinence. A group of 100 women will be randomized to:
1. Standard treatment, i.e. physiotherapy-led pelvic floor training
2. As above with the addition of 10 treatments of 30 minutes with HIFEM®.
The evaluation will be carried out regarding leakage, need for incontinence aids and pelvic floor strength immediately and six months after the intervention. The women will also rate their incontinence symptoms, physical activity level, physical function and quality of life. A group will also be interviewed about their experiences of living with incontinence and the treatment. Before the study start, a case study will be performed in which 10 women will be included. They will receive 10 treatments and measure, with the same outcomes, the effects.
Alternative treatment methods are important to meet the care needs we have today but also in the future. If treatment with HIFEM® can be effective for women over 65, it could, in addition to reducing incontinence problems and the consequences of these problems, also lead to reduced costs for society regarding care and incontinence products, as well as reduced environmental impact.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of HIFEM® Treatment of Urinary Incontinence in Women in Primary Care. A Randomized Controlled Trial
NCT06485167
High Intensity Focused Electromagnetic Field Device for Urinary Incontinence
NCT04031014
Effects of High Intensity Focused Electromagnetic Therapy With Pelvic Floor Muscle Training on Urine Leakage and Quality of Life in Primipara or Multipara Women With Stress Urinary Incontinence
NCT06638489
Urinary Stress Incontinence and Urgency in Women With EMSELLA
NCT03877640
The Effect of High-Intensity Focused Electromagnetic on Urinary Incontinence Symptoms
NCT05693103
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A - Standard Pelvic Floor Training
* Active pelvic floor muscle training led by a physiotherapist, following standard practice.
* Includes individualized advice and daily Kegel exercises to increase endurance and strength.
Pelvic Floor exercises
Pelvic floor training according to national guidelines
Arm B - Pelvic Floor Training + HIFEM
* Same physiotherapist-led training as Arm A.
* In addition: HIFEM treatment with Emsella chair.
* 10 sessions, 30 min each, over 5 weeks (2 sessions per week).
* Standardized stimulation delivered while seated, fully clothed, in a nurse-led clinic in Gothenburg.
Pelvic floor training as described in point a above, with the addition of HIFEM.
Pelvic floor training with the addition of HIFEM. The treatment will be administered over 8-10 sessions of 30 minutes each, over a period of 4-6 weeks, with two sessions per week. During treatment, the women will sit fully clothed in a treatment chair and receive standardized stimulation of the pelvic floor muscles.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pelvic floor training as described in point a above, with the addition of HIFEM.
Pelvic floor training with the addition of HIFEM. The treatment will be administered over 8-10 sessions of 30 minutes each, over a period of 4-6 weeks, with two sessions per week. During treatment, the women will sit fully clothed in a treatment chair and receive standardized stimulation of the pelvic floor muscles.
Pelvic Floor exercises
Pelvic floor training according to national guidelines
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Having daily stress incontinence requiring use of incontinence aids.
* Living in ordinary housing without home (health-) care
* Being physically active and can move independently both indoors and outdoors.
* Being able to give independent informed consent in speech and writing
* To understand and follow instructions in one of following languages Swedish, Arabic, French, and/or English
Exclusion Criteria
* Heart disease where treatment is contraindicated
* Lung disease with chronic cough
* Pacemaker, defibrillator, neurostimulator, medication pump, and implanted devices in the head or spinal cord
* Electronic or metal implants in the abdomen, hips, or knees
* Epilepsy
* Ongoing cancer
* Stoma or abdominal hernia
* Ongoing treatment with anticoagulants such as warfarin, medicines affecting the bladder such as muscarin receptor antagonist, diuretics and local oestrogen which affect the bladder and urine production.
* infection, fever, bleeding, or pain in the lower abdomen
* Skin diseases or any skin sensitivity
* BMI exceeding 30 kg/m2
65 Years
85 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Göteborg University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gothenburg university
Gothenburg, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FoU in Sweden 284879
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.